Sanofi developed the new paediatric vaccine, dubbed Vaxelis, in partnership with Merck.
PARIS: The U.S. Food and Drug Administration approved Sanofi’s new paediatric vaccine immunizing children against six diseases, the French pharmaceutical lab said on Wednesday.
Sanofi developed the new vaccine, dubbed Vaxelis, in partnership with Merck.
Vaxelis is designed for children aged 6 weeks to 4 years old and is designed to keep them from contracting diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B, and invasive disease due to Haemophilus influenza type B.
Sanofi and Merck are now working on the production and supply of Vaxelis aiming to make it available on the market in 2020 or later.
Latest posts by MD Team (see all)
- Recordati to seek Canadian approval for kidney disease drug Cystagon - April 17, 2019
- Wockhardt gets zero USFDA observations for Bioequivalence centre - April 16, 2019
- Amgen sets over Rs 15 lakh yearly price for new bone drug Evenity - April 16, 2019